Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 6/2010

01-06-2010 | Correspondence

Rifaximin for Inflammatory Bowel Disease

Author: Mario Guslandi

Published in: Digestive Diseases and Sciences | Issue 6/2010

Login to get access

Excerpt

I read with great interest the paper by Shafran and Burgunder [1] and the Editorial comment by Day and Gearry [2] about the efficacy of rifaximin in inducing and maintaining remission in patients with Crohn’s disease. …
Literature
1.
Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn’s disease activity. Dig Dis Sci. 2010;55:1079–1084.CrossRefPubMed
2.
Day AS, Gearry RB. Rifaximin and Crohn’s disease: a new solution to an old problem? Dig Dis Sci. 2010;55:877–879.CrossRefPubMed
3.
Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54.CrossRefPubMed
4.
Tamboli CP, Neut C, Desremeaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1–4.CrossRefPubMed
5.
Guslandi M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Curr Ther Res. 2004;65:292–296.CrossRef
6.
Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis. 2006;12:335.CrossRefPubMed
7.
Guslandi M. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol (in press).
Metadata
Title
Rifaximin for Inflammatory Bowel Disease
Author
Mario Guslandi
Publication date
01-06-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1245-y

Other articles of this Issue 6/2010

Digestive Diseases and Sciences 6/2010 Go to the issue

Original Article

Elevated Serum Matrix Metalloproteinase-3 and -7 in H. pylori-Related Gastric Cancer Can Be Biomarkers Correlating with a Poor Survival

Review

Interleukin10 -592 Promoter Polymorphism Associated with Gastric Cancer Among Asians: A Meta-Analysis of Epidemiologic Studies

Original Article

Outcome of a Hepatitis C Outbreak Among Patients in a Pain Management Clinic

Original Article

Ascertainment of Colonoscopy Indication Using Administrative Data

Erratum

Erratum to: Effects of Combined Pulse Electromagnetic Field Stimulation Plus Glutamine on the Healing of Colonic Anastomosis in Rats

Editorial

Pitfalls of Using Administrative Data for Research
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits